Clinical Trials Logo

Pancreatitis, Chronic clinical trials

View clinical trials related to Pancreatitis, Chronic.

Filter by:

NCT ID: NCT05733130 Recruiting - Clinical trials for Chronic Pancreatitis

Italian Registry Chronic Pancreatitis

ITARECIPE
Start date: October 10, 2022
Phase:
Study type: Observational [Patient Registry]

ITARECIPE is a multicenter national registry designed to study the diagnosis and evolution of Chronic Pancreatitis

NCT ID: NCT05713344 Recruiting - Clinical trials for Chronic Pancreatitis

Pain Phenotypes in Chronic Pancreatitis

PIP
Start date: August 1, 2021
Phase:
Study type: Observational

Chronic pancreatitis (CP) is characterised by recurrent abdominal pain. The pathological hallmarks of CP is pancreatic stellate cell activation that results in persistent inflammation and progressive fibrosis. It has been shown in various clinical and experimental studies that with disease progression there could be pancreatic neural inflammation, spinal sensitization and eventually alteration in the pain modulating architecture within the brain (widespread sensitization). These events result in different types of pain (nociceptive and neuropathic) in patients with CP, which may dynamically change during disease progression. Since the treatment for different mechanisms are unique, it becomes important to identify the predominant type of pain. Recently, pancreatic quantitative sensory testing (P-QST) has emerged as a valuable tool to identify different types of sensitization. This facility is currently available only in select centers and is being conducted under research protocols. In this study, we propose to: 1. evaluate the patterns of pain in CP and the triggers; 2. identify clinical surrogates of sensitization, i.e. neuropathic pain. The ultimate goal is to apply the best possible pain management strategy based on our research findings for patients with CP in a personalised manner.

NCT ID: NCT05692596 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Start date: October 6, 2022
Phase:
Study type: Observational

The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.

NCT ID: NCT05664880 Recruiting - Clinical trials for Chronic Pancreatitis

A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis

ALLIANCE
Start date: June 1, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this pilot study to examine the feasibility and acceptability of paricalcitol in adults with Chronic Pancreatitis (CP).

NCT ID: NCT05603702 Recruiting - Chronic Pain Clinical Trials

STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis

STTEPP
Start date: March 17, 2023
Phase: Phase 1
Study type: Interventional

The investigators propose to conduct a dose-escalation trial of an FDA-approved antiepileptic drug, lacosamide, added to opioid therapy in patients with chronic abdominal pain from chronic pancreatitis (CP). This pilot trial will test the feasibility of the study design and provide reassurance regarding the tolerability and safety of lacosamide used concomitantly with opioids in this patient population to reduce the condition known clinically as opioid-induced hyperalgesia (OIH).

NCT ID: NCT05551858 Active, not recruiting - Pain Clinical Trials

Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis

ProCP
Start date: November 17, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Chronic pancreatitis is a rare but debilitating condition associated with chronic abdominal pain, diarrhea, diabetes, and an 8-fold increased risk for the development of pancreatic cancer. Unfortunately, there is no available treatment to prevent the progression of chronic pancreatitis, and most subjects require narcotic medications to control the pain. A receptor protein call the CCK-B receptor becomes activated in chronic pancreatitis and is in part responsible for the scar tissue or fibrosis that occurs and responsible for the cancer risk. In mice with chronic pancreatitis, the inflammation and damage was reversed with an old drug called proglumide that blocks the activation of the CCK-B receptor. Proglumide has also been shown to possibly reduce pain. This protocol involved a 2-Part study to test the safety of oral proglumide in those with confirmed chronic pancreatitis and the second goal is to determine if proglumide improves pain and function of the pancreas. Part-1 is an open-labelled Lead-in Study of N=8 subjects over a 12-week treatment period. Part-2 is a randomized double blind pseudo cross over study where subjects will be treated in Arm A (placebo for 12 weeks followed by 12 weeks of proglumide) and Arm B ( proglumide for 24 weeks).

NCT ID: NCT05540197 Enrolling by invitation - Diabetes Mellitus Clinical Trials

Arginine-stimulated Indication of Early Outcome After Islet Transplantation

ALADDIN
Start date: February 23, 2023
Phase:
Study type: Observational

Through islet transplantation, functional β-cell mass can be restored. Allogeneic islet transplantation is a treatment modality for a select group of patients with complicated type 1 diabetes mellitus. For patients undergoing (partial) pancreas resection, autologous islet transplantation may help prevent complicated diabetes. Up until now, no studies have been performed on early islet graft function in the first week after transplantation. Early graft function may be a predictor for estimating long-term islet graft success. Arginine can excite β-cells to release insulin. It can thus provide an estimate of β-cell secretory capacity and can be used as an alternative to (oral) glucose tolerance tests. In this study, we aim to find a predictor model for islet graft function by assessing peak C-peptide after arginine stimulus in the early post-transplantation phase.

NCT ID: NCT05489003 Recruiting - Clinical trials for Chronic Pancreatitis

Fatigue, Psychological Comorbidity and Quality of Life Among Patients With Chronic Pancreatitis in China.

Start date: August 1, 2022
Phase:
Study type: Observational

This study will investigate the status of fatigue, psychological comorbidity and quality of life among patients with chronic pancreatitis in China and analyze their influencing factors.

NCT ID: NCT05476978 Completed - Clinical trials for Pancreatic Ductal Adenocarcinoma

Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions

Start date: July 1, 2022
Phase:
Study type: Observational

We aim to develop an EUS-AI model which can facilitate clinical diagnosis by analyzing EUS pictures and clinical parameters of patients.

NCT ID: NCT05453851 Not yet recruiting - Clinical trials for Chronic Pancreatitis

A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign Pancreatic Tumors

Start date: July 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial assesses the safety and effectiveness of total pancreatectomy with islet cell autotransplantation for the treatment of patients with long-term pancreatic inflammation (chronic pancreatitis) and non-cancerous (benign) pancreatic tumors. Total removal of the pancreas (pancreatectomy) can be used to treat chronic pancreatitis, but it may result in diabetes. An islet cell autotransplantation involves removing cells from a patient's pancreas (the islet cells) and infusing them into the liver. Islet cells are responsible for producing hormones like insulin, reducing the occurrence of diabetes in patients undergoing total pancreatectomy. Total pancreatectomy with autologous islet cell transplant is an accepted and Food and Drug Administration-approved treatment for patients with chronic pancreatitis. However, patients with chronic pancreatitis and pancreatic tumors have historically not been candidates for this procedure due to concerns of spreading potentially cancerous cells to other parts of the body. This clinical trial evaluates the safety and effectiveness of this treatment in patients with chronic pancreatitis and benign pancreatic tumors.